.png)
Reddress
Point-of-care autologous whole-blood-clot dressing for hard-to-heal wounds (ActiGraft)
Latest event found: 23 Feb 2026 · 8 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
RedDress is pursuing focused commercialization of its autologous whole-blood wound-care platform through U.S. distribution and international channel partnerships. Public evidence indicates product-led expansion rather than ownership change, with continued emphasis on ActiGraft Pro and clinical validation.
Efficiency Ratio
A small Israeli team appears to be converting a focused regenerative-wound-care platform into multiple commercial distribution channels, suggesting strong resource-to-output efficiency, although limited public evidence constrains confidence in scale.
Evidence Signals
ActiGraft was reported as officially distributed across the United States by OX BioMed.
RedDress announced a strategic partnership with Onemed for commercialization and distribution of the ActiGraft Wound Care System in the Nordic region.
Background · older than 12 months
Legacy Medical Consultants acquired the exclusive U.S. rights to sell ActiGraft Pro across hospitals, physician offices, Veterans Affairs and Department of Defense facilities, and outpatient wound-care centers.
RedDress announced that it would showcase ActiGraft at SAWC Spring 2025, highlighting randomized controlled trial data and real-world results.
ActiGraft Pro was added to the Wound Care Advantage Formulary after a comprehensive evaluation.
ActiGraft Pro was selected by Healogics Wound Care Supply for addition to its iSupply group purchasing organization.
RedDress announced randomized controlled trial results reporting that patients treated with ActiGraft Pro were more than twice as likely to heal as patients receiving standard care for diabetic foot ulcers.
- About
- Israeli advanced-wound-care company (Israel-based, with US subsidiary RedDress Inc. in Ponte Vedra Beach/Jacksonville, FL), founded in 2009 by Dr. Igal Kushnir (MD) and Alon Kushnir (CEO). Its ActiGraft / ActiGraft PRO systems create an autologous whole-blood clot at the point of care — mixing a small sample of the patient's own whole blood with a proprietary coagulation powder to form, in under five minutes, an in-vitro blood-clot tissue applied topically as a biologic scaffold and protective covering to restart the natural healing cascade. FDA 510(k)-cleared and CE-marked (2020), with US Medicare (G-code) reimbursement and a Vizient GPO contract; used in 6,000+ patients across 30 countries. Primarily for chronic/hard-to-heal wounds (diabetic, venous, pressure ulcers) but also cleared for traumatic, post-surgical and debrided wounds. Combat relevance is moderate/secondary — applicable to prolonged field care and complex/burn wound management, not acute hemorrhage control.
- Tags
- #woundcare #autologous #wholeblood #clot #chronicwounds #dfu #pointofcare #fda #regenerative